Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity INVION LIMITED ABN 76 094 730 417 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director DR GREG COLLIER Date of last notice 19 March 2019 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Change to indirect holdings. Indirect holdings are Beacon Super Fund Pty Ltd ATF Beacon Super Fund of which Dr Collier is a director and beneficiary; Barwon Biotechnology Pty Ltd of which Dr Collier is a director and shareholder; and Fusion Biosciences Pty Ltd of which Dr Collier is a director. Date of change 12 February 2019 Total No. of securities held prior to change 23,437,599 fully (indirectly held). Class Fully paid ordinary shares paid Unlisted Share Options + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 ordinary shares Appendix 3Y Change of Director’s Interest Notice Number acquired 8,333,333 Fully paid ordinary shares 136,288,073 Share options exercisable at $0.03 each on or before 12 February 2023 (IVXAT). Number disposed Nil. Value/Consideration Nil Consideration. Share Options issued following Shareholder Approval at EGM held 30 January 2019. Total No. of securities held after change 31,770,932 fully (indirectly held). Note: If consideration is non-cash, provide details and estimated valuation paid ordinary shares 136,288,073 Share options exercisable at $0.03 each on or before 12 February 2023 (IVXAT). Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Share Options issued following Shareholder Approval at EGM held 30 January 2019. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract n/a Nature of interest n/a Name of registered holder (if issued securities) n/a Date of change n/a No. and class of securities to which n/a interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired n/a Interest disposed n/a + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Value/Consideration n/a Interest after change n/a Note: If consideration is non-cash, provide details and an estimated valuation Part 3 – +Closed period Were the interests in the securities or contracts detailed n/a above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade n/a to proceed during this period? If prior written clearance was provided, on what date was this n/a provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3